Get all your news in one place.
100's of premium titles.
One app.
Start reading
Barchart
Barchart
Omor Ibne Ehsan

23andMe Stock Is Surging After a Bankruptcy Judge Cleared Genetics Business Sale. Here’s Why You Need to Stay Far Away From ME Shares.

23andMe (ME) is a genetic testing company that provides individuals with their DNA-based ancestry records. This company has the second-largest ancestry database after AncestryDNA, but has been struggling due to waning demand for one-time-use DNA kits.

Moreover, a 2023 data breach exposed 6.9 million users’ data. The data breach eroded trust and led to a $30 million lawsuit settlement. By late 2024, 23andMe laid off 40% of its workforce and shuttered its drug development arm. ME stock then plunged below the Nasdaq $1 listing requirement, and all independent board members resigned over disagreements with CEO Anne Wojcicki’s privatization push.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.